Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flora Sam

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Circulation. Heart Failure|October 8, 2009
Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid depositionAndreia Biolo, Sujata Ramamurthy, Lawreen H Connors, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2011
Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overloadMasayuki Shimano, Noriyuki Ouchi, Kazuto Nakamura, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 23, 2024
Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trialLai San Tham, Hiddo J L Heerspink, Xiaojun Wang, et al.
Circulation|July 22, 2015
Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart AssociationMerry L Lindsey, Manuel Mayr, Aldrin V Gomes, et al.
Nature Medicine|August 31, 2025
Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trialBarry A Borlaug, Jeffrey M Testani, Mark C Petrie, et al.
Nature Communications|April 5, 2025
LEOPARD: missing view completion for multi-timepoint omics data via representation disentanglement and temporal knowledge transferSiyu Han, Shixiang Yu, Mengya Shi, et al.
Circulation|April 8, 2009
A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failureMohit Jain, Aniela Jakubowski, Lei Cui, et al.
Circulation|March 24, 2020
Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group SummarySanjiv J Shah, Barry A Borlaug, Dalane W Kitzman, et al.
The Journal of Experimental Medicine|January 18, 2018
Cardiac macrophages promote diastolic dysfunctionMaarten Hulsmans, Hendrik B Sager, Jason D Roh, et al.
Journal of the American College of Cardiology|June 11, 2013
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesClyde W Yancy, Mariell Jessup, Biykem Bozkurt, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Circulation. Heart Failure|October 8, 2009
Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid depositionAndreia Biolo, Sujata Ramamurthy, Lawreen H Connors, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2011
Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overloadMasayuki Shimano, Noriyuki Ouchi, Kazuto Nakamura, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 23, 2024
Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trialLai San Tham, Hiddo J L Heerspink, Xiaojun Wang, et al.
Circulation|July 22, 2015
Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart AssociationMerry L Lindsey, Manuel Mayr, Aldrin V Gomes, et al.
Nature Medicine|August 31, 2025
Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trialBarry A Borlaug, Jeffrey M Testani, Mark C Petrie, et al.
Nature Communications|April 5, 2025
LEOPARD: missing view completion for multi-timepoint omics data via representation disentanglement and temporal knowledge transferSiyu Han, Shixiang Yu, Mengya Shi, et al.
Circulation|April 8, 2009
A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failureMohit Jain, Aniela Jakubowski, Lei Cui, et al.
Circulation|March 24, 2020
Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group SummarySanjiv J Shah, Barry A Borlaug, Dalane W Kitzman, et al.
The Journal of Experimental Medicine|January 18, 2018
Cardiac macrophages promote diastolic dysfunctionMaarten Hulsmans, Hendrik B Sager, Jason D Roh, et al.
Journal of the American College of Cardiology|June 11, 2013
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesClyde W Yancy, Mariell Jessup, Biykem Bozkurt, et al.
Pageof 9